Detalhe da pesquisa
1.
The Epidemiology of Herpes Zoster in Immunocompetent, Unvaccinated Adults ≥50 Years Old: Incidence, Complications, Hospitalization, Mortality, and Recurrence.
J Infect Dis
; 222(5): 798-806, 2020 08 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31830250
2.
Modelling the Public Health Burden of Herpes Zoster and the Impact of Adjuvanted Recombinant Zoster Vaccine in Five Selected Countries in Southeast Asia.
Infect Dis Ther
; 2024 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38493411
3.
Assessing the Underestimation of Adult Pertussis Disease in Five Latin American Countries.
Infect Dis Ther
; 12(12): 2791-2806, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38095808
4.
How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?
Hum Vaccin Immunother
; 19(1): 2164144, 2023 12 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-36821856
5.
Cost-effectiveness analysis measuring the total costs against the health benefits of three different rotavirus vaccines for Mexico.
Hum Vaccin Immunother
; 19(2): 2219189, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37339232
6.
A Cross-Sectional Concept Elicitation Study to Understand the Impact of Herpes Zoster on Patients' Health-Related Quality of Life.
Infect Dis Ther
; 11(1): 501-516, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34994924
7.
Meta-Regression of Herpes Zoster Incidence Worldwide.
Infect Dis Ther
; 11(1): 389-403, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34874546
8.
Economic burden of meningococcal disease in children and adolescents in Tijuana, Mexico.
Hum Vaccin Immunother
; 18(6): 2103319, 2022 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35921223
9.
Estimated public health impact of human rotavirus vaccine (HRV) and pneumococcal polysaccharide protein D-conjugate vaccine (PHiD-CV) on child morbidity and mortality in Gavi-supported countries.
Hum Vaccin Immunother
; 18(7): 2135916, 2022 12 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36507685
10.
Cost effectiveness and budget impact of universal varicella vaccination in Russia.
Hum Vaccin Immunother
; 18(5): 2045152, 2022 11 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35258445
11.
A systematic literature review of herpes zoster incidence worldwide.
Hum Vaccin Immunother
; 17(6): 1714-1732, 2021 06 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33651654
12.
Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany.
Hum Vaccin Immunother
; 17(12): 5296-5303, 2021 12 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34905463
13.
Estimated Public Health Impact of the Recombinant Zoster Vaccine.
Mayo Clin Proc Innov Qual Outcomes
; 5(3): 596-604, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34195552
14.
A systematic literature review to assess the burden of herpes zoster disease in China.
Expert Rev Anti Infect Ther
; 19(2): 165-179, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32997550
15.
The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy.
Hum Vaccin Immunother
; 16(2): 327-334, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31442095
16.
Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.
J Manag Care Spec Pharm
; 26(12): 1567-1575, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33043821
17.
Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older.
Dermatol Ther (Heidelb)
; 9(2): 281-297, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30929219
18.
Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
Appl Health Econ Health Policy
; 17(5): 723-732, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31250218
19.
Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme.
BMJ Open
; 9(5): e025553, 2019 05 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31061027
20.
Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old.
Hum Vaccin Immunother
; 15(1): 34-44, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30130448